OrganonMEX:OGN 59 Market Cap is MXN62,106 Mil as of Jun. 29, 2026. GuruFocus rates MEX:OGN with a GF Score™ of 59/100 and a GF Value™ of MXN246.81 (Fairly Valued). The stock has 10 warning signs investors should review. Among 1,020 Drug Manufacturers companies, Organon ranks better than 90.49% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Organon's share price for the quarter that ended in Mar. 2026 was MXN112.2. Organon's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 263 Mil. Therefore, Organon's market cap for the quarter that ended in Mar. 2026 was MXN29,469 Mil.
Organon's quarterly market cap
declined
from Sep. 2025 (MXN49,397 Mil) to Dec. 2025 (MXN33,320 Mil) and
declined
from Dec. 2025 (MXN33,320 Mil) to Mar. 2026 (MXN29,469 Mil).
Organon's annual market cap
increased
from Dec. 2023 (MXN59,569 Mil) to Dec. 2024 (MXN72,442 Mil) but then
declined
from Dec. 2024 (MXN72,442 Mil) to Dec. 2025 (MXN33,320 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Organon's Enterprise Value for Today is MXN192,670 Mil.
Organon (MEX:OGN) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Organon Market Cap Related Terms
Organon Market Cap Historical Data
* Premium members only.
The historical data trend for Organon's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:OGN vs AMRN, SCLX, MIRA: Market Cap Comparison
For the Drug Manufacturers - General subindustry, Organon's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Organon Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Organon's Market Cap distribution charts can be found below:
* The bar in red indicates where Organon's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Organon's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Organon (MEX:OGN) has a Market Cap of MXN62,106 Mil as of Jun. 29, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Organon and its competitors. According to the industry distribution chart, Organon ranks #97 out of 1020 companies in the Drug Manufacturers industry, placing it in the top 9.5%.
Is Organon's Market Cap too high?
Organon's current Market Cap is MXN62,106 Mil. Based on the distribution chart, Organon ranks #97 out of 1020 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Organon has a GF Score™ of 59/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Organon's Market Cap compare to AMRN and SCLX?
According to the Drug Manufacturers industry distribution chart, Organon ranks #97 out of 1020 companies for Market Cap. This places Organon in the top 10% of its industry — outperforming the majority of peers. The industry median Market Cap is 206.61. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 206.61, based on 1,020 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Organon and its competitors. For the Drug Manufacturers industry, the median Market Cap is 206.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Organon's current Market Cap is MXN62,106 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Organon stock overvalued right now?
Based on GuruFocus' analysis, Organon (MEX:OGN) is currently considered Fairly Valued. The stock's GF Value™ is MXN246.81, compared to a current price of MXN229.00 — trading 7.2% below its estimated fair value. The current Market Cap is MXN62,106 Mil. Organon's overall GF Score™ is 59/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Organon (MEX:OGN), the current Market Cap is MXN62,106 Mil as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Organon (MEX:OGN) Overvalued in 2026?
Based on GuruFocus' analysis, Organon stock appears to be undervalued.
The current stock price of MXN229.00 is trading 7.2% below its estimated GF Value™ of MXN246.81.
GuruFocus considers Organon to be Fairly Valued.
Key valuation signals for MEX:OGN:
Market Cap: MXN62,106 Mil
GF Value™: MXN246.81 vs. price of MXN229.00 (7.2% below fair value)
No single metric tells the full story. See the MEX:OGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
59GF Score
Get the complete analysis for MEX:OGN
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:OGN has been successfully added to your 
